Dupixent Lawsuit Attorneys

Call Now If You Used Dupixent & Got T-Cell Lymphoma

Did you use Dupixent (dupilumab) for at least one year of continuous use and then receive a cutaneous T-cell lymphoma (CTCL) diagnosis? The two events might be connected, and you might be able to demand compensation from the pharmaceutical companies who manufactured  Dupixent.

Symptoms of CTCL often include:

• Red rashes, scaly skin, and/or skin plaques
• Itching or chronic pain in the affected areas
• Swollen lymph nodes
• Unexpected or rapid weight loss
• Chronic fatigue
• Tumors or nodules, especially close to the skin
• Discolored patches of skin
• Find out if you qualify to file a Dupixent claim or lawsuit by calling Kershaw Talley Barlow today. Our nationally recognized team of attorneys and scientists helps clients nationwide with cases filed against Big Pharma and other corporations that sell unsafe products that put everyday patients and consumers in danger. If Dupixent caused your injuries, we will, we will hold potential defendants Regeneron Pharmaceuticals and Sanofi liable for any injuries and/or damages you have experienced.

You can count on us to give you the strength to seek justice and fair compensation.

Call us at (916) 520-6639 and request a free consultation to discuss your options after taking Dupixent for at least one year and being diagnosed with CTCL.

What is Dupixent?

Dupixent (dupilumab) is a prescription drug meant to treat several conditions, such as:

• Eczema
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Chronic rhinosinusitis with nasal polyps

The injectable drug binds to receptors to block proteins that are linked to inflammation. If you have struggled with inflammation-related health conditions, your doctor might have prescribed or recommended Dupixent to you.

Dupixent Linked to T-Cell Lymphoma

Although many patients have used Dupixent without incident, others have had concerning side effects and adverse events, including those that are not listed in the drug’s warning labels and use instructions. Perhaps most concerning, some medical experts and drug safety groups have noticed a potential link between Dupixent use and increased risk of developing cutaneous T-cell lymphoma. This disease is a type of non-Hodgkin’s lymphoma (NHL) that occurs in the skin, usually manifesting as rashes, lesions, and tumors throughout the body, often close to the skin. CTCL can be extremely dangerous and permanently jeopardize the immune system.

Several recent and comprehensive studies (*see below) have linked Dupixent to CTCL or worsened CTCL symptoms. One study in 2024 found that people who used Dupixent had a 300% higher risk of getting CTCL than people who did not use it. Another study that year placed the risk increase at about 350%. More concerning still, another study in 2025 estimated that the average risk increase was 450%.

According to the Food and Drug Administration (FDA), potential indications of a CTCL complication related to Dupixent use mainly include:

• Moderate-to-severe atopic dermatitis
• Moderate-to-severe asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (inflammation of the esophagus)
• Prurigo nodularis/nodular prurigo (itchy nodular skin lesions)
• Chronic obstructive pulmonary disease (COPD)
• Chronic spontaneous urticaria (occurring as hives for more than six weeks and without a known allergy)
• Bullous pemphigoid (large fluid-filled blisters on the skin)

Who Can File a Dupixent Lawsuit?

You might be eligible to file a Dupixent lawsuit if:

• You used Dupixent continuously for at least one year after it was prescribed to you for an FDA-approved condition;
• You were later diagnosed with cutaneous T-cell lymphoma (CTCL); and,
• You have not missed your state’s statute of limitations (varies).

Importantly, Dupixent lawsuits are strictly concerned with CTCL diagnoses. If you have been diagnosed with cutaneous B-cell lymphoma (CBCL), other lymphomas or blood cancers, or other skin cancers, but not CTCL, then you could be ineligible to file a Dupixent lawsuit.

Call (916) 520-6639 or contact us online now to see if you are eligible to file a Dupixent lawsuit.

Who is Liable for Dupixent Injuries?

The two primary manufacturers and marketers of Dupixent are:

• Regeneron Pharmaceuticals
• Sanofi

Lawsuits have already been filed by people who have been diagnosed with cutaneous T-cell lymphoma after using Dupixent, and they have named both Big Pharma companies as the defendants. The lawsuits argue that the companies failed, and continue to fail, to warn patients and doctors alike about the potential risk of CTCL after using Dupixent. As many claimants have pointed out, the lengthy drug data provided to the Food and Drug Administration (FDA) about Dupixent doesn’t mention CTCL risk at all.

Even if the drug manufacturers didn’t know about the risk, the argument could be made that they reasonably should have known if more safety research had been conducted before introducing the drug to the market. Also, strict product liability laws might allow injured Dupixent users like you to file a claim against Sanofi and/or Regeneron.

Compensation in Dupixent CTCL Lawsuits

At Kershaw Talley Barlow, we take the time to understand every client’s losses and injuries, so we can pursue a fair and maximized amount of compensation. For your Dupixent lawsuit, we will want to understand how your life has been affected by your Dupixent prescription, including but not limited to the harm caused by cutaneous T-cell lymphoma.

Compensation that we might be able to demand in your Dupixent claim includes:

• Medical treatment costs, including long-term care related to cancer treatments
• Pain, suffering, and hardships caused by living with CTCL
• Lost wages and reduced income-earning capacity
• Wrongful death if you lost a loved one to CTCL

Our Dupixent attorneys are  ready to fight for you.

Choose Kershaw Talley Barlow for Your Dupixent Claim

Bringing a claim against a Big Pharma company is never easy. If you’re not represented by a knowledgeable and experienced attorney, it can be downright intimidating. If you were diagnosed with cutaneous T-cell lymphoma after using Dupixent, give yourself the strength, knowledge, and support you need by coming to Kershaw Talley Barlow. From our office in Sacramento, California, we have helped countless clients nationwide with injury claims and lawsuits filed against drug manufacturers.

People trust their difficult cases with us because:

• We have recovered more than $1 billion in settlements and verdicts on behalf of injured plaintiffs nationwide.
• We have more than 100 years of combined legal experience with a focus on cases that go to court.
• We are nationally recognized for our scientific expertise and ability to apply rigorous scientific methods to strategically position your case.
• We have been featured many times in major news outlets and media, such as Forbes®, ABC News, and CBS News.
• We have numerous awards and recognitions, such as the HIPAA Seal of Compliance, Best Lawyers®, Super Lawyers®, and more.

You deserve world-class legal counsel. That’s what we deliver at Kershaw Talley Barlow.

To get a free case review with our Dupixent lawyers, call (916) 520-6639 at any time.

*More Information From Studies and Articles

• “Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study” (published in the National Library of Medicine)
• “Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis” (published in Wiley Only Library)
• “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study” (published in the National Library of Medicine)
• “Acceleration of cutaneous T-cell lymphoma following dupilumab administration” (published in National Library of Medicine)